News Hub | News Direct

Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy

NTRB

The global transdermal patch market is quietly gaining ground. Valued at $7.8 billion in 2023, it is projected to reach nearly $10.95 billion by 2030. Within that, pain patches are leading the way, expected to grow from $4.8 billion in 2021 to $7.3 billion by 2031. But this growth is not just about convenience. Transdermal drug delivery is solving critical problems, from managing chronic pain in aging populations to delivering medications without needles. Most importantly, it offers a safer alternative to traditional opioid use. The abuse-deterrent opioid segment, while still relatively small, is gaining momentum. It is projected to more than double between 2024 and 2030, driven by regulatory pressure, clinical demand, and advances in technology. That convergence is starting to attract serious investor interest. This creates a promising setup for small-cap biopharma companies focused on innovative pain and rescue therapies. Several are moving closer to meaningful catalysts such as New Drug Application submissions and early-stage commercial progress. Here are a few stocks positioned to benefit from this overlooked but vital shift in drug delivery. Nutriband Inc. (NASDAQ: NTRB) is positioning itself as a disruptive force in the opioid pain management space with its lead product candidate, AVERSA Fentanyl, a transdermal patch designed to deter abuse, misuse, and accidental exposure. At the core of this innovation is Nutriband’s proprietary AVERSA technology, which leverages an aversive agent coating to address the most common form of fentanyl patch abuse—oral consumption. According to a 2022 market analysis by Health Advances, AVERSA Fentanyl has the potential to reach peak annual US sales of between 80 million and 200 million dollars. Unlike many early-stage biotechs, Nutriband is generating revenue today. Through its Pocono Pharma subsidiary, which produces kinesiology tape now sold in retail giants like Walmart, Walgreens, Target, and CVS, the company recorded 667 thousand dollars in revenue in the first quarter of 2025, a 63 percent year-over-year increase. This revenue stream helps fund development and reduces dilution risk, a key differentiator in a capital-intensive sector. Development of AVERSA Fentanyl continues to progress. Nutriband recently completed the commercial manufacturing process scale-up with its partner Kindeva Drug Delivery, a global CDMO that produces millions of transdermal patches annually. Together, they are preparing to file an Investigational New Drug application with the FDA, a crucial step ahead of the planned human abuse liability clinical study. The company is pursuing the 505(b)(2) pathway, which may allow for a faster and more efficient route to market. Regulatory momentum is supported by growing recognition of the public health risks tied to transdermal opioid misuse. AVERSA Fentanyl is aligned with the FDA’s Opioids Action Plan and has been engineered to make fentanyl patches safer without restricting access for legitimate patients. The product may also benefit from regulatory pressure to shift all fentanyl patch formulations toward abuse-deterrent formats, similar to previous changes required for oxycontin generics. Nutriband’s AVERSA platform is protected by a broad international IP portfolio with patents issued in 46 countries. Most recently, the company was granted a US patent for its transdermal abuse-deterrent system in June 2025, further strengthening its competitive moat. Nutriband’s inclusion in the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth indexes signals growing institutional awareness. Management believes this milestone reflects accelerating progress toward building shareholder value and positioning AVERSA Fentanyl as a potential category leader in opioid safety. With real revenue, a large addressable market, strong IP, and a progressing regulatory timeline, Nutriband Inc. offers investors early exposure to a unique solution in the fight against opioid abuse. Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is quietly becoming a standout in the pain and neuropsychiatry treatment markets, driven by consistent revenue growth, expanding product reach, and shareholder-focused capital allocation. In the first quarter of 2025, Collegium reported net revenue of 177.8 million dollars, up 23 percent year-over-year, with its ADHD medication Jornay PM growing prescriptions by 24 percent and generating 28.5 million dollars in revenue for the quarter. The company has now completed a major field force expansion, bringing its ADHD sales team to approximately 180 representatives to support continued growth in this space. The company’s core pain portfolio also continues to deliver. In Q1 2025, Collegium generated 149.2 million dollars in revenue from its chronic pain medications, with each of its flagship products—Belbuca, Xtampza ER, and the Nucynta franchise—posting year-over-year growth. Belbuca alone brought in 51.7 million dollars, up 2 percent, while Xtampza ER and Nucynta added 47.6 million and 47.1 million, respectively. Collegium’s strong financial performance has supported aggressive yet balanced capital deployment. In May, the company announced a 25 million dollar accelerated share repurchase, part of a broader 150 million dollar program, reflecting confidence in its long-term value. The company ended Q1 with 197.8 million dollars in cash, up from 162.8 million at year-end 2024, and generated over 55 million dollars in cash from operations. With reaffirmed full-year guidance, expanding leadership, and strong product execution, Collegium is establishing itself as a consistent revenue generator in the biopharma space. Its dual focus on responsibly managed pain treatments and a fast-growing ADHD franchise gives it a diversified growth engine in two high-need therapeutic areas. For investors seeking a profitable, commercial-stage biotech with upside potential and disciplined management, Collegium deserves a closer look. Assertio Holdings, Inc. (Nasdaq: ASRT) is a specialty pharmaceutical company in transition, executing a focused strategy to strengthen its commercial platform while shedding legacy risks. In the first quarter of 2025, the company reported 26 million dollars in total net product sales, tracking in line with its full-year guidance. Management emphasized that sales from its growth assets, particularly Rolvedon and Sympazan, are outperforming internal expectations, providing a strong foundation for Assertio’s near-term revenue expansion. Assertio is actively streamlining operations and reducing legal exposure, having settled multiple longstanding lawsuits, including the DOJ False Claims Act case and opioid-related liabilities. A major structural move was the divestiture of Assertio Therapeutics, which held legacy legal obligations and low-value assets. That transaction has now fully removed Assertio Holdings and its current subsidiaries from all opioid litigation. This cleanup effort allows management to focus entirely on high-potential assets and business development. Rolvedon, a treatment for chemotherapy-induced neutropenia, continues to show momentum, with Q1 sales outperforming despite prior-quarter inventory stocking. Management expects steady growth for the product throughout 2025. Sympazan, a prescription oral film for Lennox-Gastaut syndrome, also benefited from a revised promotional strategy, driving a 6.5 percent year-over-year increase in prescriptions during the quarter. With a cleaned-up balance sheet, narrowed commercial focus, and a disciplined approach to portfolio expansion, Assertio is entering a new phase. The company aims to become a preferred partner in specialty pharma, leveraging its commercial infrastructure to onboard new products across therapeutic areas. For investors seeking a turnaround story with defined growth levers and reduced legal overhang, Assertio may be one to watch in 2025. Aquestive Therapeutics, Inc. (Nasdaq: AQST) is a pharmaceutical company focused on advancing medicines that improve patients’ lives through innovative science and delivery technologies. The company develops orally administered products to deliver complex molecules, offering novel alternatives to invasive standard therapies. Aquestive currently has four licensed commercial products marketed globally and serves as the exclusive manufacturer for these products. It also collaborates with pharmaceutical partners using proprietary technologies like PharmFilm and has established drug development and commercialization capabilities. The company is progressing a late-stage proprietary candidate, Anaphylm™, an oral sublingual film for severe allergic reactions including anaphylaxis, alongside an early-stage epinephrine prodrug topical gel, AQST-108, targeting dermatological conditions such as alopecia areata. In Q1 2025, Aquestive submitted its NDA for Anaphylm and is preparing for a potential U.S. launch in early 2026, pending FDA approval. The NDA includes comprehensive adult and pediatric clinical data demonstrating a pharmacokinetic profile consistent with existing epinephrine autoinjectors. Aquestive has expanded its market access and medical affairs teams and is advancing commercial readiness, including plans for regulatory submissions in key international markets. The FDA assigned a PDUFA target action date of January 31, 2026, and may convene an Advisory Committee meeting during the review process. Sales of royalty-based products such as Sympazan® and Azstarys® contributed to revenue during the quarter, while manufacturing revenue declined due to lower Suboxone® volumes but was partially offset by growth in other collaborations. Total revenue for Q1 2025 was $8.7 million, down 28% from $12.1 million in Q1 2024. Research and development expenses decreased slightly, while selling, general, and administrative expenses rose primarily due to regulatory and commercial investments linked to Anaphylm’s launch preparations. Aquestive reported a net loss of $22.9 million for the quarter and held $68.7 million in cash at March 31, 2025. The company has paused sales and marketing activities for Libervant® following a court decision affecting its approval status, with plans to resume patient access in 2027 or sooner if permitted. Aquestive revised its 2025 revenue guidance to $44 to $50 million and non-GAAP adjusted EBITDA loss guidance to $47 to $51 million, reflecting the impact of this change. With its innovative, non-invasive epinephrine treatment nearing regulatory approval, broad IP protection, and a clear commercial strategy, Aquestive is positioned to offer a meaningful new option for patients with severe allergic reactions and to expand its footprint in specialty pharmaceutical delivery. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting LLC to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

July 02, 2025 06:00 AM Eastern Daylight Time

News Release

Rising Concerns Over Systemic Risks in the US Leveraged Loan Market

AM Europe

A new study from the University of Bath has issued a stark warning: systemic risks in the US leveraged loan market are growing, potentially setting the stage for another financial crisis. This concern is amplified by several factors, including an increase in underpriced loans, the prominent role of less-regulated non-bank lenders, and deteriorating loan standards. Leveraged loans are typically extended to companies with significant existing debt or less robust credit histories, making them inherently riskier. While lenders are compensated with higher interest rates for this elevated risk, recent trends suggest a dangerous imbalance. The University of Bath study, published on June 25, 2025, highlights that highly leveraged loans are increasingly being underpriced, particularly by non-bank lenders who operate with less regulatory oversight than traditional banks. Default rates on US leveraged loans have already surged, reaching a four-year high of 7.2% in December 2024, according to the Financial Times. Many borrowers are resorting to "distressed exchanges" to avoid outright bankruptcy, a move that reduces investor recoveries and underscores the fragility of the market. Key contributing factors to the escalating risks include: Weakening Pricing of Leverage Risk: The study points out a dramatic weakening in how leverage risk is priced since 2014, with the risk premium declining most for the riskiest borrowers. This distortion reflects fundamental structural weaknesses in the post-2014 leveraged lending landscape. Rise of Non-Bank Lenders: The shift towards non-bank originators for credit has been a significant development. These "shadow lenders" are not subject to the same stringent regulations as traditional banks, leading to concerns about unchecked risk-taking and a lack of transparency. While some states have commercial lending licensing requirements for non-bank lenders, a comprehensive federal framework is absent. Surge in Securitization (CLOs): The rapid growth in Collateralized Loan Obligation (CLO) issuance plays a crucial role. CLOs package these leveraged loans into securities, which are then sold to investors. While this transfers risk away from the original lenders, it also creates complex, opaque structures where the ultimate investors may lack clear information about the underlying assets. Approximately 70% of the US leveraged loan market is now accounted for by CLOs. Declining Loan Standards ("Covenant-Lite" Loans): A widespread adoption of "covenant-lite" loans further exacerbates the risk. These loans come with fewer protective clauses for lenders, giving borrowers more flexibility even when their financial health deteriorates. This erosion of loan standards can make it harder for lenders to intervene and mitigate losses in the event of distress. Regulators have begun to express heightened concern over the rapid growth and increasing interconnections within the private credit market, which largely comprises non-bank lenders and their leveraged loan activities. The sheer size of this market means that any significant disruption could pose a systemic threat to financial stability. While some past assessments, such as a 2020 GAO report, suggested that leveraged lending did not significantly threaten stability during the COVID-19 pandemic, the current environment with increased underpricing and diminished oversight presents a renewed challenge. The confluence of underpriced risk, unregulated shadow banking, and relaxed lending standards paints a concerning picture for the US leveraged loan market. The Parallel World of Personal Loans for Bad Credit While the leveraged loan market deals with corporate debt, a distinct but equally dynamic segment exists for individual consumers with less-than-perfect credit scores: personal loans for bad credit. This market has seen consistent growth, often driven by demand for debt consolidation. As of Q1 2025, nearly half of all personal loan borrowers utilize these funds to consolidate or refinance existing debt, particularly high-interest credit card balances. However, access to these loans comes at a significant cost; while average personal loan rates in June 2025 hover around 12.65%, borrowers with low credit scores face considerably higher Annual Percentage Rates (APRs), often reaching into the triple digits for very low scores. This segment is heavily serviced by online lenders and fintech companies, many of whom employ alternative data and underwriting models to assess risk beyond traditional credit scores, sometimes even offering "no credit check" loans. While these options provide crucial access to credit for those otherwise excluded, they often carry short repayment terms and exceptionally high fees, raising concerns about potential debt traps. Contact Details Josh J. Bradley +1 515-323-4161

July 01, 2025 04:21 AM Eastern Daylight Time

News Release

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

ADIA LCTX MESO CRSP

The global stem cell market is estimated at $15.10 billion in 2024 and is projected to nearly double to $28.89 billion by 2030, growing at a compound annual growth rate of 11.4 percent. This growth is driven by advances in regenerative medicine, increasing investments, and new therapies targeting serious diseases such as cancer, autoimmune disorders, and genetic conditions. Stem cells offer a unique ability to repair and regenerate damaged tissue, providing potential treatments that address the root causes of illnesses rather than just managing symptoms. Major factors fueling this expansion include greater government funding, breakthroughs in cell therapy technology, and growing acceptance of stem cell treatments within the medical community. Both large pharmaceutical companies and smaller biotech firms are contributing to the rapidly evolving landscape, pushing the boundaries of what’s possible with regenerative medicine. Now let’s take a look at some promising players in this segment. Adia Nutrition Inc. (OTCQB: ADIA) is quickly establishing itself as a rising player in the regenerative medicine space, operating at the intersection of cutting-edge stem cell science and accessible patient care. Through its two core divisions, Adia Labs and Adia Med, the company offers both premium nutritional supplements and advanced clinical therapies, including umbilical cord blood stem cells and autologous hematopoietic stem cell transplantation, also known as aHSCT. A major milestone came in June when Adia Nutrition launched its first nationwide television commercial for Adia Vita, marking a watershed moment in the company’s growth. The ad, created by its subsidiary Adia Labs and powered by the MNTN connected TV platform, introduces Adia Vita’s groundbreaking formula to a national audience. With 100 million viable stem cells and 3 trillion exosomes per dose, Adia Vita sets a new standard in the $15.1 billion global stem cell market. In an industry where inconsistent quality is common, this product is designed to deliver reliable potency and open new possibilities for patients and physicians. The commercial encourages viewers to speak with their doctors about Adia Vita, underscoring the legal ability of licensed physicians to use FDA-registered biologic products off-label when they believe it is in the best interest of the patient. The company’s progress throughout 2025 reflects strong execution on multiple fronts. In just six weeks, Adia completed its uplisting from the OTC Pink Sheets to the OTCQB Venture Market, far ahead of the usual 12- to 16-week timeline. This achievement followed an independent audit, full compliance with SEC Rule 15c2-11, and the cancellation of 25 million undocumented shares. These steps, along with the removal of Adia’s shell risk designation and the formation of Adia Labs LLC, have significantly boosted investor confidence and expanded opportunities for market participation. At the heart of Adia’s therapeutic offering is Adia Vita, which received FDA registration in March, allowing for national distribution. This regulatory milestone affirms Adia Labs' role as a serious biomanufacturing partner. Licensed clinics in the United States, Colombia, and Mexico have already begun adopting the Adia Med brand under exclusive sourcing agreements. These partner clinics receive access to FDA-registered, cGMP-compliant products and in-depth training designed to uphold the highest quality standards. In addition to stem cell products, Adia is expanding its clinical pipeline to include advanced procedures like therapeutic plasma exchange. Already offered at the flagship Winter Park clinic, this treatment filters harmful substances from the bloodstream and has shown promise in conditions like Alzheimer’s disease, autoimmune disorders, and post-COVID complications. These therapies utilize the same advanced apheresis machines used in aHSCT, increasing both clinical efficiency and technical scalability. Accessibility remains a cornerstone of Adia’s model. While traditional regenerative therapies often cost between fifteen thousand and thirty-five thousand dollars, Adia is working to lower the barrier to entry through vertical integration and payment programs like the Cherry Payment Plans. These financing options help extend care to a wider population, aligning with Adia’s mission to democratize access to advanced treatments. Regulatory progress is also accelerating. The Winter Park location, which opened in January, has received full approval from Florida’s Agency for Health Care Administration. This approval allows the clinic to accept insurance, creating a pathway to tap into the four point nine trillion dollar US health insurance market. The development is especially important in Florida, where more than 4.5 million residents are over the age of sixty-five and increasingly in need of treatments for neurodegenerative and autoimmune conditions. Legislative support is adding momentum. Florida Senate Bill 1768, which takes effect July first, will expand legal access to regenerative therapies for orthopedic injuries, wound healing, and pain management. Adia is already working with partner clinics to bring these services online and plans to host open house events at the Winter Park location to engage the community and raise awareness about this policy shift. Between its national television debut, rapid uplisting, FDA product registration, expanding clinical network, and patient-friendly pricing strategies, Adia Nutrition is executing a bold multi-front strategy. For investors seeking early exposure to a small-cap innovator with strong regulatory tailwinds, real clinical adoption, and a clear roadmap for national expansion, ADIA presents a compelling opportunity. Mesoblast (Nasdaq: MESO) (ASX: MSB) is an emerging innovator in regenerative medicine, focused on developing off-the-shelf cellular therapies for serious inflammatory diseases. Its core platform is based on mesenchymal stromal cells, or MSCs, which respond to immune system overactivation by releasing anti-inflammatory factors. This approach is designed to reduce the underlying inflammation that drives many hard-to-treat conditions. The company’s lead product, Ryoncil, recently became the first and only FDA-approved MSC therapy in the United States. It is now available for children as young as two months who are suffering from steroid-refractory acute graft-versus-host disease, a severe and often deadly condition. Since its commercial launch in March, Mesoblast has quickly onboarded more than 20 transplant centers, exceeding expectations. Access to Ryoncil is expanding rapidly. The therapy is now covered for over 220 million insured lives across the United States. This includes fee-for-service Medicaid coverage in 37 states, with full national Medicaid coverage expected on July 1. Commercial payers have also added Ryoncil to formularies or made it available through prior authorization or medical exception. The result is broad access for nearly every eligible patient in the country. Ryoncil also benefits from strong regulatory protections. The FDA granted it seven years of orphan-drug exclusivity, which blocks approval of competing MSC therapies for the same indication through 2032. Biologic exclusivity runs through 2036, and key patents extend well into the 2040s. These layers of protection help lock in a strong competitive position as the company continues expanding. Mesoblast is not stopping with the pediatric market. A pivotal trial to support label expansion into adult graft-versus-host disease is being planned in partnership with the NIH-funded Bone Marrow Transplant Clinical Trials Network. This would significantly increase Ryoncil’s commercial potential. Meanwhile, the company is advancing Revascor, an investigational MSC therapy for ischemic heart failure with reduced ejection fraction. The program has received RMAT designation from the FDA and has completed two randomized controlled trials. A recent Type B meeting with the agency resulted in alignment on manufacturing and product release standards as well as the proposed design for a confirmatory trial. These steps move Mesoblast closer to filing for accelerated approval. Mesoblast is still early in its commercial journey, but the progress is meaningful. With one FDA-approved product, growing insurance coverage, late-stage pipeline assets, and a strong intellectual property moat, the company is positioning itself as a serious contender in the future of cell-based therapies. Lineage Cell Therapeutics (NYSE: LCTX) is carving out a differentiated lane in regenerative medicine with off-the-shelf, allogeneic cell therapies targeting major unmet needs in ophthalmology and neurology. The company uses pluripotent stem cells to manufacture specialized cells that can replace damaged tissue, and its strategy is beginning to show long-term durability. The lead program, OpRegen, is focused on geographic atrophy in dry age-related macular degeneration. Lineage is co-developing the therapy with Genentech through a global partnership that included a fifty million dollar upfront payment and the potential for over six hundred million in milestones. The ongoing GAlette Phase 2a trial is now enrolling patients, with Lineage providing clinical and manufacturing support. Recent three-year follow-up data from a prior Phase 1/2a trial showed that patients who received broad coverage from OpRegen experienced an average improvement of nine letters on the standard visual acuity test. These gains held steady across the full three years. In a disease that normally leads to irreversible decline, this type of durability is rare. Retinal imaging also showed structural improvements, adding further evidence of biological activity. OpRegen is designed to be a one-time treatment. That matters in a market where current options require frequent injections and have shown limited long-term benefit. If larger trials confirm the early results, Lineage and Genentech could be in a position to disrupt the standard of care. The company is also advancing OPC1, a therapy for spinal cord injuries using oligodendrocyte progenitor cells. The program already has RMAT and Orphan Drug designations. A new trial called DOSED is now underway to evaluate a next-generation delivery system in both subacute and chronic patients. Early coverage in the media has highlighted some promising signs of motor function recovery. Lineage reported $47.9 million in cash at the end of March 2025, giving the company a projected runway into the first quarter of 2027. First-quarter revenue came in at $1.5 million, driven by its Genentech collaboration. Net loss dropped to $4.1 million, down from $6.5 million in the same quarter last year. Pipeline development is expanding as well. Lineage is moving into auditory neuron regeneration, photoreceptor replacement, and a next-generation hypoimmune cell platform. The goal is to unlock more high-impact indications using the same core manufacturing expertise. For small-cap biotech investors looking for staying power, real data, and credible partners, Lineage is starting to look like a serious name. The company has cash in the bank, clinical traction, and a scalable model that could support meaningful growth in the years ahead. CRISPR Therapeutics (NASDAQ: CRSP) continues to solidify its role as a leader in gene editing, transitioning from a research-stage innovator to a commercial-stage biotech with global reach. CRSP made history with the approval of CASGEVY, the first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, now launched across multiple countries, including the US, EU, UK, and UAE. More than 65 treatment centers have been activated worldwide, and over 90 patients have already had cells collected. Patient initiations are expected to accelerate in 2025, and Vertex, CRSP’s commercial partner, has secured national reimbursement agreements in key markets, including England, Austria, and the Middle East. While CASGEVY generates increasing momentum, CRSP is aggressively expanding into cardiovascular disease through its in vivo editing platform. CTX310, targeting ANGPTL3, has shown peak reductions of up to 82 percent in triglycerides and 86 percent in LDL in a Phase 1 trial, with a favorable safety profile across all cohorts. These results represent early validation of CRSP’s lipid nanoparticle delivery platform and highlight the potential for once-and-done gene editing to address atherosclerotic cardiovascular disease. Full Phase 1 data for CTX310 will be presented at a medical meeting later this year. CRSP is also advancing CTX320, targeting the LPA gene in patients with elevated lipoprotein(a), a genetically driven and currently untreatable risk factor for major adverse cardiovascular events. An updated data readout is expected in the first half of 2026. Preclinical progress continues on CTX340, aimed at treating refractory hypertension by editing angiotensinogen (AGT), and CTX450 for acute hepatic porphyria. In immuno-oncology and autoimmune disease, CRSP is developing next-generation allogeneic CAR T-cell therapies. CTX112, targeting CD19, and CTX131, targeting CD70, are both in clinical trials. CTX112 has already earned RMAT designation from the FDA for relapsed or refractory lymphoma and is being evaluated across both oncology and autoimmune indications, including lupus and systemic sclerosis. Updates on both programs are expected later this year. CRSP also holds a manufacturing facility in Massachusetts to support its cell therapy pipeline from clinical to commercial scale. Beyond gene editing, CRISPR is expanding its therapeutic toolkit through a new collaboration with Sirius Therapeutics. The partnership centers on SRSD107, a long-acting small interfering RNA therapy targeting coagulation Factor XI. Phase 1 data showed FXI activity reductions of more than 93 percent and sustained effects for up to six months after a single dose. A Phase 2 trial is launching in patients undergoing knee surgery to evaluate SRSD107’s anticoagulant potential with reduced bleeding risk. CRSP will lead commercialization in the US, while Sirius retains China rights. The agreement also includes two additional siRNA programs CRSP may license in the future. Financially, CRSP remains well-capitalized with $1.86 billion in cash and marketable securities as of March 31. Net loss for the quarter widened slightly to $136 million as the company scaled operations and collaboration expenses related to CASGEVY. However, its pipeline breadth, global partnerships, and differentiated platforms provide strong positioning for long-term upside as gene editing moves further into real-world medicine. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

June 30, 2025 07:00 AM Eastern Daylight Time

News Release

Drone-as-a-Service Set to Nearly Triple to $31 Billion by 2030: Four Stocks to Watch

ZENA RCAT LIDR UAVS

The Drone-as-a-Service (DaaS) market is experiencing unprecedented growth, driven by advancements in technology and increasing demand across various sectors. In the United States, the commercial drone services market is projected to expand from $12.55 billion in 2025 to $31.13 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of approximately 19.92%. This surge is propelled by regulatory advancements, such as the Federal Aviation Administration's (FAA) initiatives to streamline operations and integrate drones into the national airspace system. A significant driver of this growth is the increasing adoption of drones in government and defense applications. Drones are now integral in surveillance, infrastructure inspection, logistics, and reconnaissance missions, offering cost-effective and efficient solutions. The U.S. Department of Defense has recognized the strategic importance of unmanned aerial systems, leading to substantial investments and partnerships with private companies. This dynamic landscape presents a unique opportunity for investors to engage with companies at the forefront of the DaaS sector. With favorable policies, technological advancements, and a growing market, the DaaS industry is poised for continued expansion and innovation. Let's take a look at a few promising stocks. ZenaTech Inc. (Nasdaq: ZENA) stands out as a compelling leader in the emerging Drone as a Service (DaaS) sector, especially with its clear focus on government and defense applications. Since its founding in 2017, ZenaTech has combined AI drone technology with enterprise SaaS and quantum computing to address mission-critical tasks such as inspection, monitoring, surveying, safety, and compliance. Its wholly owned subsidiary, ZenaDrone, designs and manufactures multifunctional autonomous drones tailored for a broad range of industries, including agriculture, logistics, commercial land surveying, and, notably, defense. The company’s DaaS model is designed to eliminate barriers for business and government customers who want to use advanced drone technology without incurring upfront costs for hardware, pilot training, or regulatory compliance. This subscription-like service offers scalability that allows clients to adjust usage based on operational needs, streamlining legacy processes that have traditionally relied on manual labor or expensive equipment. Recent announcements highlight ZenaTech’s aggressive expansion through strategic acquisitions targeting land survey and civil engineering firms with strong federal government client bases. These acquisitions in Virginia, North Carolina, South Carolina, and Florida are fueling the company’s growth in the US Southeast, a key region for infrastructure and defense projects. The target companies bring expertise in land surveys critical to highway, bridge, and development projects and hold active contracts with federal and state agencies. According to CEO Shaun Passley, Ph.D., “This acquisition reinforces our DaaS business model expansion objectives to provide drone innovation supporting US federal government, defense, and infrastructure surveying.” ZenaTech also benefits from a supportive regulatory environment. The June 2025 White House executive order accelerating FAA approvals and prioritizing American-made, National Defense Authorization Act-compliant drones creates a favorable market backdrop for the company’s US manufacturing and go-to-market plans. The ZenaDrone 1000, a rugged military-grade drone with AI, thermal imaging, LiDAR, and multi-spectral sensors, exemplifies the company’s ability to deliver scalable, mission-ready solutions that meet stringent federal standards. Financially, ZenaTech demonstrated strong momentum in the first quarter of 2025, with revenues nearly doubling year over year to $1.13 million, driven by both organic growth and acquisition activity. The company plans over 20 acquisitions within the next 12 months to build a national DaaS footprint. Investments in engineering, testing facilities, and government relations partnerships underscore its commitment to expanding defense and federal sales channels. Overall, ZenaTech’s blend of cutting-edge drone technology, scalable DaaS offerings, strategic acquisitions in government-aligned land surveying, and alignment with favorable federal policies position it well to capitalize on rapid growth in the drone survey market, which is expanding globally at over 19 percent annually. AgEagle Aerial Systems Inc. (NYSE: UAVS ) is building one of the most relevant drone technology stacks for federal and international deployment, with active exposure to agriculture, infrastructure, public safety, and defense-aligned projects. As a full-stack UAS provider with its own sensors, drones, and software, AgEagle fits squarely into the thesis of Drone-as-a-Service expansion powered by land survey and data solutions. The company’s recent inclusion in a high-level White House discussion on FAA Part 108 regulations shows it is already shaping the next wave of federal drone policy. CEO Bill Irby emphasized that “streamlined regulation will allow broader deployment of autonomous data solutions and open the door for increased economic activity.” Finalization of these BVLOS rules would allow AgEagle’s drones to operate beyond line of sight, a crucial capability for large-scale survey missions in both civil and defense settings. AgEagle is also scaling its global presence. The company just announced its 100th drone sale to South Korea and entered a manufacturing alliance in India with Vyom Drones to serve one of the world’s largest agricultural markets. This complements a recent collaboration with Ascent AeroSystems, integrating AgEagle’s RedEdge-P multispectral camera with rugged all-weather UAV platforms for mission-critical agricultural and infrastructure applications. Financially, the company has sharply reduced operating expenses, grown margins to 58.5 percent, and posted $7.06 million in net income for Q1 2025, a 211 percent improvement year over year. Drone sales nearly doubled compared to the same quarter last year. With improved financial footing, regulatory momentum, and strategic global partnerships, AgEagle stands out as a serious operator in the growing UAS sector. For investors tracking government-aligned DaaS models, AgEagle offers a well-positioned, diversified platform ready to scale into regulated airspace and global survey markets. Red Cat Holdings Inc. (Nasdaq: RCAT) is one of the most defense-aligned drone companies in the public market, with clear exposure to U.S. military procurement, federal policy support, and domestic manufacturing expansion. The company’s flagship product, the Black Widow, is a small unmanned aerial system already awarded a Program of Record designation under the U.S. Army’s Short Range Reconnaissance initiative. This status makes Black Widow one of the few sUAS platforms formally accepted for field use by the Army. Through its subsidiaries Teal Drones and FlightWave Aerospace, Red Cat offers a Family of Systems that spans multiple mission types, including fixed-wing VTOL drones, military-grade tricopters, and precision strike FPV drones. In May, Red Cat partnered with ESAero to increase certified aerospace manufacturing capacity to meet rising demand for Black Widow units, with production capacity expected to reach one thousand units per month. Red Cat is not just a hardware player. It is also integrating advanced AI and computer vision capabilities from partners including Palantir and Athena AI, enhancing the performance of its drones in GPS-contested environments. Palantir’s Visual Navigation software is being added to Red Cat’s autonomous systems, and the company is also using Palantir’s Warp Speed platform to streamline production and improve efficiency. Regulatory alignment is also playing in Red Cat’s favor. The company publicly supported recent White House executive orders prioritizing U.S.-manufactured drones and accelerating their use across government and commercial sectors. Brendan Stewart, Vice President of Regulatory Affairs, called the orders a signal that the U.S. is “serious about enabling a secure domestic drone industry.” With new facilities, added global reach, strong federal alignment, and fresh capital from a recent forty-six million dollar equity raise, Red Cat is executing a clear strategy to dominate the defense-focused DaaS market with scalable, American-made drone platforms. AEye Inc. (Nasdaq: LIDR) is developing software-defined lidar technology that could become foundational to government and defense-focused Drone-as-a-Service models. Lidar, or light detection and ranging, is a laser-based sensing method that creates real-time 3D maps of physical environments. It is essential in sectors like autonomous navigation, battlefield terrain mapping, infrastructure inspection, and weather-resilient data collection—use cases where drones increasingly replace manned systems and GPS struggles. AEye’s flagship sensor, Apollo, can detect vehicles and objects at over one kilometer with industry-leading precision. It is the only high-performance 1550 nm lidar designed to integrate behind the windshield, giving it flexibility in both automotive and unmanned deployments. Apollo is now in volume production through Tier 1 manufacturer LITEON, marking a major step toward scaling. The company recently joined a GM-sponsored research initiative at the University of Toronto focused on autonomous driving in poor weather, which underscores how AEye’s technology addresses a known gap in lidar systems. In China, Apollo just won the Intelligent Perception Industry Leadership Award, adding global validation. AEye is also now integrated with Nvidia’s Drive platform, which opens the door to commercial OEM deals. Financially, AEye has cut operating costs by 75 percent, raised $24 million over the past year, and extended its cash runway into mid-2026. Scaling will depend on customer contracts, but manufacturing is in place and inventory is ready. For investors looking at DaaS companies acquiring sensing and surveying tools with federal relevance, AEye offers a small-cap, pure-play exposure to precision lidar with growing validation and a capital-light path to production. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ZenaTech Ltd. to assist in the production and distribution of content related to ZENA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

June 27, 2025 06:00 AM Eastern Daylight Time

Back to the Doctor’s Office: As Telehealth Declines, Demand for In-Person Care Drives a Medical Real Estate Shift

The Hoyt Organization

In the wake of the COVID-19 pandemic, virtual healthcare saw a historic surge. But now, a new trend is emerging: patients are returning to their doctors' offices — and they’re doing it in droves. According to new data from the Center for Telehealth and e-Health Law (CTeL), telehealth use has entered a steady decline since its peak during the pandemic. With the expiration of emergency policies that once expanded access to virtual care, analysts project a staggering 12 million telehealth appointments will be lost annually. This shift is placing renewed importance on brick-and-mortar medical practices—and driving an urgent need for physical medical office space in urban hubs across the country. “This isn’t just a statistical dip — it’s a fundamental shift,” says Kurt Hackett, Vice President of Asset Management at Rethink Capital, which owns and manages the Medical Pavilion at 939 Ellis Street in San Francisco. “We're seeing patients of all types of medical disciplines re-emphasize the value of in-person care, and providers are responding by ramping up their physical presence.” A Premier Option in San Francisco's Healthcare Corridor At the heart of the resurgence of in-person care is the Medical Pavilion at 939 Ellis Street, a premier medical office building situated in San Francisco’s vibrant healthcare corridor along Van Ness Avenue. Nestled close by Sutter Health’s CPMC Van Ness Campus, the Pavilion offers a strategic, central location for healthcare providers looking to expand or relocate to a high-demand urban market. “939 Ellis Street is perfectly positioned for providers who need immediate access to hospital systems, public transit, and city and suburban population,” says Hackett. “It checks all the boxes for modern medical delivery.” The property features: Proximity to top-tier health systems and medical campuses Full and partial floor suites to accommodate a wide range of medical uses Infrastructure designed to meet today’s clinical and compliance needs On-site parking, and mass transit accessibility What’s Driving the In-Person Comeback? Several factors are contributing to the retreat from telehealth and the renewed interest in physical appointments: Clinical Limitations of Virtual Care: While video consultations offer convenience, many conditions — such as orthopedic and cardiac issues, cancer care, and urological disorders — require physical examinations, lab work, and imaging that simply cannot be done remotely. Insurance Reimbursement Reversions: As emergency-era policies sunset, insurers are reverting to pre-COVID reimbursement models which often favor in-person visits. This reimbursement structure creates an incentive for providers to bring patients back into the office. Digital Fatigue: After years of Zoom meetings, online learning, and virtual appointments, both patients and providers are reporting burnout with screen-based interactions. Trust and Patient Experience: Research continues to show that face-to-face care fosters stronger patient-provider relationships and improves long-term treatment outcomes—something digital platforms have struggled to replicate. Investment Strategies Follow the Trend For real estate investors and healthcare providers alike, the shift back to in-person care is shaping portfolio decisions in key metro markets like San Francisco, where aging medical stock and strong population density make modern medical offices particularly attractive. “Providers are increasingly seeking newer, well-located facilities that reflect the current standards of care,” Hackett explains. “Our goal at the Medical Pavilion is to offer not just square footage, but an ecosystem where quality care can thrive.” A New Era of Care Delivery As the pendulum swings away from virtual-first healthcare, the demand for high-quality, strategically located medical office space is expected to grow — particularly in regions like the Bay Area, where healthcare innovation and patient demand continue to intersect. For providers seeking to adapt and grow in this changing environment, properties like the Medical Pavilion at 939 Ellis Street represent a unique opportunity: the chance to be part of San Francisco’s healthcare future, right in the heart of its medical corridor. For leasing inquiries at 939 Ellis St., contact Trask Leonard, president and CEO of Bayside Realty Partners at tleonard@baysiderp.com. About Medical Pavilion at 939 Ellis Street: Positioned in the Van Ness medical hub, Medical Pavilion at 939 Ellis Street is a purpose-built medical office building offering flexible, large-scale space options for healthcare users, with direct access to public transit, nearby hospitals, and the city’s primary healthcare corridor. It can accommodate a range of specialties. It boasts a scenic rooftop terrace and available parking. Contact Details Leeza Hoyt +1 310-343-3197 llhoyt@hoytorg.com Company Website https://939-ellis.com/

June 26, 2025 08:00 AM Pacific Daylight Time

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market

Medicus Pharma Ltd (MDCX)

Skin cancer is the most common form of cancer in the United States, with more than 9,500 cases getting diagnosed every day. In fact, more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. The most common form of skin cancer is basal cell carcinoma (BCC), which accounts for over 5 million cases of all skin cancers diagnosed in the U.S. each year. Currently, the standard treatment for most BCC patients is surgery, either standard excision or Mohs micrographic surgery, which has led to a significant unmet medical need for a non-surgical option. That is why Medicus Pharma Ltd. (NASDAQ:MDCX), a life sciences company focused on accelerating the clinical development programs of novel therapeutic assets, has been attracting investor attention with its revolutionary new treatment that is under development. A non-invasive novel approach Medicus, through its wholly owned subsidiary SkinJect Inc., is focused on commercializing a novel, non-invasive treatment for basal cell carcinoma using a patented dissolvable microneedle patch. The patch is thumb-sized, and what makes it particularly unique is its ability to deliver a chemotherapeutic agent (doxorubicin) to kill tumor cells on the skin and induce a memory immune response to prevent cancer recurrence. Microneedles are promising devices for painless drug delivery, which can improve the biological effect of drugs through adjustable drug release. This novel non-invasive regimen to treat skin cancer, especially BCC, therefore represents a potentially attractive alternative to surgery and current topical therapeutic options. So far, preliminary trial results have been quite promising. The company completed a Phase I study for SkinJect in March 2021 for participants with superficial and nodular BCC, which met its primary objective of safety and tolerability. In January 2024, a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that began enrollment in August with 60 patients. According to Medicus, an interim analysis of the ongoing clinical study reveals that SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%. In April this year, the company announced that the Institutional Review Board (IRB) had approved an increase in the number of patients from 60 to 90, further highlighting the company’s progress towards validation. The company plans to submit the interim analysis to the FDA as part of a package seeking a Type C meeting with the regulator in Q2 2025 with the aim of seeking approval to fast-track the clinical development program. At the same time, the company has said that it will be expanding the phase 2 clinical study into additional sites in the US from the current nine sites as well as two clinical trial sites in Europe. In addition to that, Medicus has received the study may proceed approval from the UAE Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC. The study is expected to randomize 36 patients in four sites in the UAE. It’s also important to note that the company hasn't limited SkinJect to treating humans only. Last year Medicus received a Minor Use in Major Species Designation (MUMS) for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. MUMS is a designation that is comparable to orphan drug status for human medications. Earlier this month, the company revealed that it had submitted a comprehensive product development plan to treat external SCC under Investigational New Animal Drug, designed to seek concurrence of the FDA under MUMS designation. Significant revenue opportunity As mentioned earlier, the potential addressable market for SkinJect is quite significant. About 40–50% of Americans who live to age 65 will experience BCC or SCC at least once. And while still most prevalent in the older segments of the population, it is becoming ever more frequent in younger individuals. BCC procedures are projected to grow at 4% per annum, reaching 6 million procedures in 2030, representing a market size in excess of $15 billion annually, and Medicus is well positioned to capture a significant share of this market if SkinJect is approved due to a couple of reasons. For starters, it is a less painful, less invasive way to treat skin cancer and also lowers the likelihood of recurrence. Secondly, while Mohs surgery costs range between $2,000 and $15,000, the cost of three SkinJect microneedle patches is estimated at $1,000, illustrating the potential for significant cost savings for patients. Furthermore, SkinJect can be administered the same day as a diagnosis, while the average lead time for surgery in the US spans 2–8 months. Apart from that, the overall incidence of SCC in horses is 2-3%, and recent estimates of the US horse population range from 6.6 to 7.25 million horses. With only a handful of approved oncology drugs in the veterinary market, the company believes that developing a non-invasive treatment for equine SCC represents an untapped and unmet market opportunity potentially in the range of $250 million. Medicus has continued to show its commitment to unlocking more shareholder value with its recent announcement of a binding letter of intent to acquire Antev Ltd. for $75 million in a share exchange transaction. Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Collectively, this represents an additional $6 billion in potential market opportunities for Medicus. Antev shareholders will receive an aggregate 19% equity stake in Medicus, plus $65 million in additional contingent payments tied to potential future FDA Phase 2 and New Drug Application approvals. The transaction is expected to close before the end of June. Takeaway Medicus recently announced the closing of its $7 million public offering, which will be used to fund its Phase 2 proof-of-concept clinical trial, further illustrating investor confidence in the company’s progress so far and future prospects. As such, investors searching for a unique opportunity in the cancer treatment space should consider taking a closer look at Medicus before it gains mainstream traction. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 24, 2025 07:00 AM Eastern Daylight Time

New Alvarez & Marsal Report on Tariff Impact Highlights the Imperative for Companies to Use Current Turmoil as License to Radically Improve Operations

Alvarez & Marsal Consumer and Retail Group

Apparent calm masks deeper volatility – inaction now is high risk Delay will show up in future quarterly reporting Quantify total tariff exposure and identify equivalent cost cutting opportunities This moment of crisis should not be wasted The Consumer and Retail Group of Global professional services firm Alvarez & Marsal (A&M CRG) today released a special report, Tariffs & Turmoil – Never Let a Good Crisis Go To Waste, which urges retailers to take bold, immediate action as global trade policies shift and economic pressures mount. The report challenges companies to break free from “wait-and-see” or “wing it” paralysis and seize the current disruption as a strategic reset. “We are in a false moment of calm, but July 9th is right around the corner. While the latest quarterly results may not yet show the impact, companies that fail to act now will see tariffs hit hard in the quarters ahead,” said Joanna Rangarajan, Managing Director in Alvarez & Marsal’s Consumer and Retail Group and co-author of the study. “They should be looking to identify every opportunity to improve and fortify operations, as those who successfully came out of Covid did.” Co-author Michael Prendergast, Managing Director in Alvarez & Marsal’s Consumer and Retail Group, noted: “What we are seeing is a shell-shocked level of inactivity. Companies need to use this tariff crisis as an opportunity to do the hard work of getting their SG&A numbers down by 15 to 20 percent. Looking at pricing, reaching out to vendor bases and shifting country of origin are no longer enough. This is the perfect moment for management teams to refocus on optimizing their inventory, speeding up calendaring, and ultimately assessing their total cost of tariffs so that they can work toward an equivalent level of budgetary savings.” The report lays out nine areas in which retail companies should be focusing to navigate tariff twists and turns successfully, including: Relentlessly reduce costs across the entire organization Fuel innovation and growth initiatives that differentiate Double down on product winners that drive value Price intelligently to spark demand without sacrificing margin Adopt a fast fashion calendar mindset to increase agility Make decisions at lightning speed – favor action over perfection Reshape sourcing strategy for flexibility and long-term advantage Optimize supply chains for efficiency and responsiveness Establish a cross-functional command center with clear accountability To download a pdf of Tariffs & Turmoil – Never Let a Good Crisis Go To Waste, please visit: https://alvarezandmarsal-crg.com/insight/tariffs-turmoil-never-let-a-good-crisis-go-to-waste/ The Alvarez and Marsal Consumer and Retail Group (CRG) is a management consulting firm that tackles the most complex challenges and advances its clients, people, and communities towards their maximum potential. CRG combines the best of A&M’s broader firm's bias toward action and practicality with deep consumer and retail industry experience. CRG partners with businesses across a wide range of categories including Food & Beverage, Beauty & Personal Care, Grocery, Mass Merchandise, and Apparel & Footwear to drive significant performance improvement. Contact Details David Schneidman dschneidman@alvarezandmarsal.com Company Website https://alvarezandmarsal-crg.com/

June 18, 2025 11:00 AM Eastern Daylight Time

American Battery Materials Announces Expansion of Strategic Focus to Include Magnesium Recovery at Utah’s Paradox Basin

American Battery Materials Inc

American Battery Materials, Inc. (OTC PINK: BLTH) ("ABM"), a U.S.-based company dedicated to advancing critical mineral resource development, today announced that it is expanding its strategic extraction efforts beyond lithium to include magnesium recovery at its flagship project in Utah’s Paradox Basin. The Paradox Basin resource—already recognized for its lithium concentrations—also contains high levels of Magnesium. ABM’s mineral rights cover 743 claims across 14,260 acres, offering a unique opportunity to co-extract lithium and magnesium using advanced Direct Lithium Extraction (DLE) techniques. “Expanding our efforts to recover magnesium is a natural progression of our mission to support the U.S. energy transition,” said David E. Graber, CEO of American Battery Materials. “With demand for lightweight metals growing across the defense, aerospace, and automotive industries, developing a domestic magnesium supply chain is vital for national competitiveness and sustainability.” Magnesium, recently identified as a critical material by the U.S. Department of Energy and the Department of Defense, is essential in a variety of high-growth sectors, including electric vehicles, electronics, biodegradable medical implants, and lightweight structural components. ABM’s DLE-based approach is designed to efficiently recover both lithium and magnesium with minimal environmental impact. The company’s closed-loop extraction system returns the majority of extracted brine to its source, significantly reducing land usage and eliminating the need for open-pit mining or evaporation ponds. About American Battery Materials, Inc. American Battery Materials, Inc., headquartered in Greenwich, Connecticut, is a U.S.-based company focused on the exploration, acquisition, and development of lithium and other battery materials critical to the global energy transition. ABM is committed to sustainable practices and delivering value to its stakeholders through strategic partnerships and innovative projects. For Media Inquiries: American Battery Materials, Inc. 500 West Putnam Avenue, Suite 400 Greenwich, CT 06830 +1 800-998-7962 ir@americanbatterymaterials.com To the extent that statements contained in this press release are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management. Words such as "believe," "goal," "plan," "feel," "may," "will," "expect," "anticipate," "estimate," "intend," "target" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Reports on Form 10-Q, including but not limited to the discussion under "Risk Factors" therein, which the Company has filed with the SEC and may be viewed at http://www.sec.gov. Contact Details Investor Relations +1 800-998-7962 ir@americanbatterymaterials.com Company Website https://www.americanbatterymaterials.com/

June 18, 2025 07:00 AM Eastern Daylight Time

News Release

GET OSHA Courses Now Offering Authorized OSHA 30 Certification Across the US

Rev Up Marketers

As workplace safety regulations tighten and demand for certified professionals surges, Get OSHA Courses is stepping up with an innovative, user-friendly platform offering OSHA 30 online and other OSHA training online, transforming how American workers and companies approach safety. With a mission to simplify access to OSHA certification online, Get OSHA Courses delivers fast, 100% online OSHA 30-Hour Training that meets OSHA guidelines, fits into busy schedules, and doesn’t break the bank. From construction workers to warehouse staff and safety officers, the platform is designed for everyone looking to advance their safety knowledge and meet legal compliance requirements, anytime, anywhere. A Smarter Way to Get OSHA 30 Certified OSHA 30 is an essential certification for workers and supervisors of high-hazard professions. This incorporates construction, general industry as well as warehousing. It’s part of the 30-hour OSHA Outreach Training Program. In many states, it’s required by law for various jobs. It’s often a must for job eligibility, too. Get OSHA Courses stands out in a crowded market by offering: Excellent OSHA 30 Online training course material. Instant access with self-paced modules. Mobile-friendly platform for on-the-go learning. Printable OSHA Safety Certification upon completion. Official OSHA DOL Plastic Card. Round-the-clock customer support. Group discounts for businesses & bulk training orders This efficient process helps workers finish their OSHA 30 Certification quickly. Companies can train teams without interrupting their operations. Meeting a Growing Need Across the U.S As industries grow after COVID, safety remains a top concern. The U.S. Department of Labor is doing a lot to sensitize people on the dangers at work. Due to the increased pressure, the demand of quality OSHA 30-Hour Training programs has increased tremendously. In response, we scaled rapidly to meet nationwide needs, helping thousands of professionals get certified and stay legally compliant, from New York City skyscraper crews to manufacturing hubs in Texas and beyond. Trusted by Workers. Respected by Employers. Backed by industry-recognized partners and aligned with OSHA guidelines, we ensure that certifications should be legitimate and also respected by employers across all 50 states. Whether it's for individuals looking to advance their careers or businesses seeking to quickly certify their teams, the platform's flexibility and compliance-first approach make it a reliable partner. An Invitation to Train Smarter, Not Harder With an ever-evolving regulatory landscape, OSHA 30 training online is not only mandatory; it's essential. We are not just offering another online class; it’s providing a reliable, affordable pathway to workplace safety, job advancement, and peace of mind. Those seeking OSHA 30 Online or other OSHA safety certification options can sign up today and begin training immediately. Businesses interested in group enrollments can contact the team directly for custom solutions. About Get OSHA Courses Get OSHA Courses is an online safety training platform dedicated to delivering fast, affordable, and accessible OSHA certification online. With a focus on OSHA 30-Hour Training, the company serves thousands of workers and businesses nationwide, helping them stay compliant, job-ready, and safe on the job. Contact Details Get OSHA Courses Shawn Malik +1 218-503-5891 support@getoshacourses.com Company Website https://getoshacourses.com

June 17, 2025 07:45 AM Eastern Daylight Time

peran+perawat+dalam+pencegahan+gagal+ventilasi+pada+pasien+covid+19

Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy

Rising Concerns Over Systemic Risks in the US Leveraged Loan Market

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

Drone-as-a-Service Set to Nearly Triple to $31 Billion by 2030: Four Stocks to Watch

Back to the Doctor’s Office: As Telehealth Declines, Demand for In-Person Care Drives a Medical Real Estate Shift

Medicus Pharma Ltd. (NASDAQ:MDCX): Novel Treatment For Basal Cell Carcinoma Could Upend The $15 Billion Market

New Alvarez & Marsal Report on Tariff Impact Highlights the Imperative for Companies to Use Current Turmoil as License to Radically Improve Operations

American Battery Materials Announces Expansion of Strategic Focus to Include Magnesium Recovery at Utah’s Paradox Basin

GET OSHA Courses Now Offering Authorized OSHA 30 Certification Across the US